Challenges in Management of Hairy Cell Leukemia in 2019

A Friday Satellite Symposium preceding the 61st ASH Annual Meeting and Exposition

Location

Orange County Convention Center
9800 International Dr. Room W307
Orlando, FL 32819

Registration enables you to receive CME credit for this symposium. CME credit will be provided by The Ohio State University Center for Continuing Medical Education (CCME). If you have questions or encounter any issues when registering for this symposium, contact Anna Lambertson, Executive Director of the Hairy Cell Leukemia Foundation, by email anna@hairycellleukemia.org or by phone 224-355-7201.

Speakers

Dr. Claire Dearden, The Royal Marsden Hospital, UK

Dr. Michael Grever, The Ohio State University Comprehensive Cancer Center-The James, USA

Dr. Robert J. Kreitman, National Cancer Institute, NIH, USA

Dr. Enrico Tiacci, Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia, Italy

Agenda

7:00 am Registration and Breakfast

7:30 am Welcome and Introduction

7:40 am Biological Features of Hairy Cell Leukemia and Their Clinical Implications - Dr. Enrico Tiacci, Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia, Italy

8:15 am Management of Classic Hairy Cell Leukemia and Its Complications - Dr. Michael Grever, The Ohio State University Comprehensive Cancer Center-The James, USA

8:50 am Safe and Effective Use of Moxetumomab Pasudotox for Patients with Relapsed and Refractory Hairy Cell Leukemia - Dr. Robert J. Kreitman, National Institutes of Health, USA

9:25 am Challenges in Management of Variant Hairy Cell Leukemia - Dr. Claire Dearden, The Royal Marsden Hospital, UK

10:00 am Q&A and Concluding Remarks

Symposium Description and Educational Objectives

This CME-certified symposium will provide information on current developments in the management of hairy cell leukemia (HCL). Progress in the management of patients with HCL has resulted in high response rates and improved survival. Yet, patients will relapse or be unresponsive to initial therapy and may require additional treatment. 

HCL is rare and physicians may encounter a limited number of patients with this disease throughout their career. As a result, physicians may have limited experience in re-treating patients if the patients relapse or do not respond to first-line therapy. They may also have limited experience in diagnosing variant HCL and distinguishing it from the classic form of hairy cell leukemia, as well as in managing HCL in the event of rare complications or serious life-threatening infections and pancytopenia. Furthermore, most physicians will have limited experience in treating patients with moxetumomab pasudotox, a drug approved by the FDA in 2018 for patients with relapsed or refractory HCL. 

This symposium will include speakers with expertise in the molecular pathogenesis, diagnosis and management of hairy cell leukemia. The speakers will illustrate novel therapies and major challenges in HCL through the most up-to-date research and case-based presentations.

Upon completion of this activity, participants should be better able to:

• Describe how to manage rare complications associated with hairy cell leukemia
• Outline how to make a correct diagnosis of HCL and distinguish classic HCL from variant HCL
• Identify the correct time to initiate therapy
• Name new options for management of care when patients relapse or fail to respond to therapy
• Outline how to manage patients with pancytopenia and active infections
• Describe the pathogenesis of HCL and its targetable genetic lesions

Continuing Medical Education Credit

The Ohio State University Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Ohio State University Center for Continuing Medical Education (CCME) designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™.

 
 

This symposium is supported by an educational grant from Innate Pharma.